ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0029

Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Review and Meta-Analysis

Syed Hasan1, Aali Furqan2, Afia Salman3, hira Khan4, Sarah Aslam5, Alishba Rizvi4, Hafsah Alim Ur Rahman3, Muhammad Ahmed Ali Fahim3, Madiha Salman3, Eman Ali3, Yumna Furqan6, Shanta bai7, Farah Yasmin8 and Muhammad Sohaib Asghar9, 1Dow University of Health Sciences, Karachi, PK., Karachi, Sindh, Pakistan, 2University of North Texas Health Science Center (UNT HSC), Texas, TX, 3Dow University of Health Sciences, Karachi, Pakistan, 4dow medical college, Karachi, Pakistan, 5Dow International Medical College, Karachi, Pakistan, 6Texas A&M School of Medicine, Dallas, TX, 7Liaquat National Hospital and Medical College, Karachi, Pakistan, 8Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, 9AdventHealth, Sebring, FL

Meeting: ACR Convergence 2024

Keywords: meta-analysis, Osteoarthritis, Total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteoarthritis (OA) is among the most common debilitating conditions, causing disability and pain in older adults. For end-stage OA, total knee replacement (TKR) is a common surgical modality deployed in patients with OA. Some studies have highlighted the prevalence of knee osteoarthritis in people with type 2 diabetes (T2DM). Considering that metformin is one of the most prescribed diabetic medications worldwide and has proved to be associated with weight loss, anti-inflammatory, chondroprotective as well as improved insulin resistance properties, we sought to assess the effect of metformin and the risk of TKR by performing this meta-analysis.

Methods: MEDLINE/PubMed, Cochrane Library, Embase, SCOPUS, and ClinicalTrials.gov were searched from inception to May 2024. Studies were eligible if they included “metformin”, “total knee replacement”, and “total knee arthroplasty” along with a description of the effect of metformin on the reduction of risk of TKR in patients with T2DM. The Newcastle-Ottawa Scale (NOS) tool was employed for the assessment of risk of bias in non-randomized studies.

Results: A total of 4 studies with a total of 115,182 participants, were included in our analysis. The median duration of the studies was 11 (9-15.4) years. Our primary outcome of interest was TKR. Pooled data from all four studies showed a significant decrease in the risk of TKR associated with metformin use (RR: 0.59; 95% CI: 0.38 to 0.90; P=0.02; I2:86%) (Figure 1). The heterogeneity declined upon odd-one-out analysis (RR: 0.82; 95% CI: 0.71 to 0.93; P=0.003; I2: 0%). Moreover, upon conducting the meta-regression, males were significantly associated with a greater incidence of TKR under Metformin use when compared with females (coefficient: 0.0498).

Conclusion: In patients with T2DM, regular use of metformin showed a significant decrease in the risk of TKR. Males under Metformin therapy were comparably associated with higher incidence of TKR when compared with females. The certainty of our findings is limited to the paucity of the available data that explores the relationship between Metformin and TKR.

Supporting image 1

Forest plot for Total Knee Replacement among patients under Metformin therapy vs. Non-Metformin therapy.


Disclosures: S. Hasan: None; A. Furqan: None; A. Salman: None; h. Khan: None; S. Aslam: None; A. Rizvi: None; H. Alim Ur Rahman: None; M. Fahim: None; M. Salman: None; E. Ali: None; Y. Furqan: None; S. bai: None; F. Yasmin: None; M. Asghar: None.

To cite this abstract in AMA style:

Hasan S, Furqan A, Salman A, Khan h, Aslam S, Rizvi A, Alim Ur Rahman H, Fahim M, Salman M, Ali E, Furqan Y, bai S, Yasmin F, Asghar M. Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/effect-of-metformin-on-the-incidence-of-total-knee-replacement-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-metformin-on-the-incidence-of-total-knee-replacement-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology